|
ATE102631T1
(de)
|
1988-11-11 |
1994-03-15 |
Medical Res Council |
Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
|
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
US6291159B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
|
ES2341666T3
(es)
|
1991-12-02 |
2010-06-24 |
Medimmune Limited |
Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
|
|
DK0751992T3
(da)
|
1994-03-08 |
2006-03-06 |
Human Genome Sciences Inc |
Karendotelvækstfaktor 2
|
|
US7186688B1
(en)
|
1994-03-08 |
2007-03-06 |
Human Genome Sciences, Inc. |
Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
|
|
US6608182B1
(en)
|
1994-03-08 |
2003-08-19 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 2
|
|
US7109308B1
(en)
|
1994-03-08 |
2006-09-19 |
Human Genome Sciences, Inc. |
Antibodies to human vascular endothelial growth factor 2
|
|
US7153827B1
(en)
|
1994-03-08 |
2006-12-26 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 and methods of use
|
|
US5932540A
(en)
|
1994-03-08 |
1999-08-03 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
US6040157A
(en)
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
ES2176484T3
(es)
*
|
1995-08-18 |
2002-12-01 |
Morphosys Ag |
Bancos de proteinas/(poli)peptidos.
|
|
WO1997021728A1
(en)
|
1995-12-12 |
1997-06-19 |
Karolinska Innovations Ab |
PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
|
|
US6141769A
(en)
|
1996-05-16 |
2000-10-31 |
Resilience Corporation |
Triple modular redundant computer system and associated method
|
|
US6696251B1
(en)
|
1996-05-31 |
2004-02-24 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
|
US6300065B1
(en)
*
|
1996-05-31 |
2001-10-09 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
|
GB9701425D0
(en)
*
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
JP2010213725A
(ja)
*
|
1998-01-20 |
2010-09-30 |
Univ Illinois |
タンパク質の酵母細胞表面ディスプレイおよびその使用
|
|
WO1999045959A1
(en)
*
|
1998-03-13 |
1999-09-16 |
Dana-Farber Cancer Institute, Inc. |
Humanized antibody and uses thereof
|
|
EP0953639A1
(en)
*
|
1998-04-30 |
1999-11-03 |
Boehringer Ingelheim International GmbH |
FAPalpha-specific antibody with improved producibility
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
US7153655B2
(en)
|
1998-06-16 |
2006-12-26 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
|
|
US6846655B1
(en)
|
1998-06-29 |
2005-01-25 |
Phylos, Inc. |
Methods for generating highly diverse libraries
|
|
EP1131428A2
(en)
*
|
1998-11-19 |
2001-09-12 |
Incyte Pharmaceuticals, Inc. |
Immunoglobulin superfamily proteins
|
|
US6787638B1
(en)
*
|
1998-12-02 |
2004-09-07 |
Applied Molecular Evolution, Inc. |
Tumor specific human monoclonal antibodies and methods of use
|
|
HUP0105044A3
(en)
|
1999-01-15 |
2004-07-28 |
Biogen Inc Cambridge |
Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
|
|
US7223724B1
(en)
|
1999-02-08 |
2007-05-29 |
Human Genome Sciences, Inc. |
Use of vascular endothelial growth factor to treat photoreceptor cells
|
|
US7060670B1
(en)
|
1999-05-05 |
2006-06-13 |
Neurochem (International) Limited |
Stereoselective antifibrillogenic peptides and peptidomimetics thereof
|
|
GEP20063774B
(en)
|
1999-06-01 |
2006-03-27 |
Biogen Idec Inc |
Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
|
|
US20090233806A1
(en)
*
|
1999-07-06 |
2009-09-17 |
Carr Francis J |
Protein isolation and analysis
|
|
PT1144607E
(pt)
|
1999-07-20 |
2009-04-22 |
Morphosys Ag |
Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto
|
|
US7351540B1
(en)
*
|
2000-03-17 |
2008-04-01 |
Merck Patent Gmbh |
Protein isolation and analysis
|
|
JP2001275682A
(ja)
*
|
2000-03-31 |
2001-10-09 |
Kankyo Meneki Gijutsu Kenkyusho:Kk |
抗マラチオンモノクローナル抗体をコードする遺伝子
|
|
GB0008419D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Bioinvent Int Ab |
A method for invitro molecular evolution of antibody function
|
|
MXPA02010011A
(es)
|
2000-04-11 |
2003-04-25 |
Genentech Inc |
Anticuerpos multivalentes y usos para los mismos.
|
|
PT2308982E
(pt)
*
|
2000-04-17 |
2015-03-04 |
Dyax Corp |
Métodos para construir bibliotecas de pacotes genéticos que representam os membros de uma família diversificada de péptidos
|
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
|
AU2005200250B2
(en)
*
|
2000-05-08 |
2007-10-25 |
Celldex Therapeutics, Inc. |
Human monoclonal antibodies to dendritic cells
|
|
US7521047B2
(en)
|
2000-05-12 |
2009-04-21 |
Gpc Biotech Ag |
Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
|
|
EP1156062A1
(en)
*
|
2000-05-12 |
2001-11-21 |
GPC Biotech AG |
Immunomodulatory human MHC class II antigen-binding peptides/proteins
|
|
US20040019187A1
(en)
*
|
2000-05-12 |
2004-01-29 |
Zoltan Nagy |
Immunomodulatory human mhc class II antigens-binding polypeptides
|
|
JP4955185B2
(ja)
|
2000-06-29 |
2012-06-20 |
アボット・ラボラトリーズ |
二重特異性抗体ならびに作製方法および使用方法
|
|
WO2002009755A2
(en)
|
2000-07-27 |
2002-02-07 |
Genentech, Inc. |
Apo-2l receptor agonist and cpt-11 synergism
|
|
MXPA02003434A
(es)
|
2000-08-04 |
2002-09-02 |
Human Genome Sciences Inc |
Factor de crecimiento endotelial vascular 2.
|
|
US7879540B1
(en)
|
2000-08-24 |
2011-02-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
|
US7420030B2
(en)
|
2000-09-08 |
2008-09-02 |
The Board Of Regents Of The University Of Texas System |
Aminopeptidase A (APA) targeting peptides for the treatment of cancer
|
|
US20050074747A1
(en)
*
|
2000-09-08 |
2005-04-07 |
Wadih Arap |
Biopanning and rapid analysis of selective interactive ligands (brasil)
|
|
US20040170955A1
(en)
*
|
2000-09-08 |
2004-09-02 |
Wadih Arap |
Human and mouse targeting peptides identified by phage display
|
|
US7452964B2
(en)
*
|
2001-09-07 |
2008-11-18 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of targeting peptides against placenta and adipose tissues
|
|
US7051028B2
(en)
*
|
2000-11-15 |
2006-05-23 |
Ndsu-Research Foundation |
Concurrency control in high performance database systems
|
|
ATE352040T1
(de)
|
2000-11-17 |
2007-02-15 |
Univ Rochester |
In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
CA2436595C
(en)
|
2000-12-08 |
2011-11-08 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US9249229B2
(en)
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
|
AU2011223997B2
(en)
*
|
2000-12-18 |
2013-09-19 |
Dyax Corp. |
Focused Libraries of Genetic Packages
|
|
ES2430857T3
(es)
|
2000-12-18 |
2013-11-22 |
Dyax Corp. |
Bibliotecas focalizadas de paquetes genéticos
|
|
US7402312B2
(en)
|
2001-04-13 |
2008-07-22 |
Human Genome Sciences, Inc. |
Antibodies to vascular endothelial growth factor 2 (VEGF-2)
|
|
BRPI0209792B8
(pt)
|
2001-04-13 |
2021-05-25 |
Biogen Idec Inc |
anticorpo anti-vla-1, composição que o compreende, ácido nucléico e vetor, bem como métodos in vitro para determinar o nível de vla-1 em tecido e para identificar inibidor de domínio i de integrina
|
|
MXPA03009408A
(es)
|
2001-04-13 |
2004-01-29 |
Human Genome Sciences Inc |
Factor de crecimiento endotelial vascular 2.
|
|
US20040010376A1
(en)
*
|
2001-04-17 |
2004-01-15 |
Peizhi Luo |
Generation and selection of protein library in silico
|
|
US7117096B2
(en)
*
|
2001-04-17 |
2006-10-03 |
Abmaxis, Inc. |
Structure-based selection and affinity maturation of antibody library
|
|
EP1390741B1
(en)
*
|
2001-04-17 |
2012-10-31 |
Abmaxis, Inc. |
Structure-based construction of human antibody library
|
|
AU2002314495A1
(en)
*
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
GB0115841D0
(en)
|
2001-06-28 |
2001-08-22 |
Medical Res Council |
Ligand
|
|
US20040176290A1
(en)
*
|
2001-07-18 |
2004-09-09 |
Renata Pasqualini |
Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
EP1425694A2
(en)
|
2001-08-03 |
2004-06-09 |
Medical Research Council |
Method of identifying a consensus sequence for intracellular antibodies
|
|
US20040048243A1
(en)
*
|
2001-09-07 |
2004-03-11 |
Wadih Arap |
Methods and compositions for in vitro targeting
|
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
WO2003035679A2
(en)
|
2001-10-25 |
2003-05-01 |
Medical Research Council |
Molecules
|
|
US7175983B2
(en)
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
|
WO2003044036A1
(en)
*
|
2001-11-19 |
2003-05-30 |
Applied Molecular Evolution, Inc. |
Tumor specific monoclonal antibodies
|
|
US7115716B2
(en)
*
|
2001-11-19 |
2006-10-03 |
Eli Lilly And Company |
Tumor specific monoclonal antibodies
|
|
PT1461428E
(pt)
|
2001-12-03 |
2012-05-29 |
Alexion Pharma Inc |
Método para produção de anticorpos híbridos
|
|
US7241444B2
(en)
*
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
US20080193445A1
(en)
*
|
2002-01-18 |
2008-08-14 |
Liliane Goetsch |
Novel anti-IGF-IR antibodies and uses thereof
|
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
|
US20040110226A1
(en)
*
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
MY147019A
(en)
|
2002-03-13 |
2012-10-15 |
Biogen Idec Inc |
Anti-alpha v beta 6 antibodies
|
|
MXPA04009683A
(es)
|
2002-04-09 |
2005-01-11 |
Biogen Idec Inc |
Metodos para el tratamiento de condiciones relacionadas a tweak.
|
|
US7262012B2
(en)
|
2002-05-17 |
2007-08-28 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
|
|
CN105175535A
(zh)
|
2002-05-22 |
2015-12-23 |
艾斯巴技术-诺华有限责任公司 |
在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
|
|
WO2003100000A2
(en)
*
|
2002-05-24 |
2003-12-04 |
Tularik Inc. |
Amplification and overexpression of oncogenes
|
|
US20030232387A1
(en)
*
|
2002-06-14 |
2003-12-18 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind alphaE integrin
|
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
|
AU2003254064A1
(en)
*
|
2002-08-07 |
2004-02-25 |
Tularik Inc. |
Amplification and overexpression of oncogenes
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
GB0226729D0
(en)
*
|
2002-11-15 |
2002-12-24 |
Medical Res Council |
Intracellular antibodies
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
EP1627062A1
(en)
|
2003-05-14 |
2006-02-22 |
Domantis Limited |
A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
|
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20040248189A1
(en)
*
|
2003-06-05 |
2004-12-09 |
Grzegorz Bulaj |
Method of making a library of phylogenetically related sequences
|
|
NZ544486A
(en)
|
2003-06-13 |
2009-04-30 |
Biogen Idec Inc |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
|
WO2004112575A2
(en)
*
|
2003-06-20 |
2004-12-29 |
Amgen Inc. |
Gene amplification and overexpression in cancer
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
DE10346627A1
(de)
*
|
2003-10-08 |
2005-05-19 |
Weiss, Stefan, PD Dr. |
Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung
|
|
JP5414972B2
(ja)
*
|
2003-12-23 |
2014-02-12 |
バイオキット， エセ．アー． |
病原体感染の検出のための組成物および方法
|
|
SI2511297T1
(sl)
|
2004-02-06 |
2015-07-31 |
Morphosys Ag |
Proti -CD38 humana protitelesa in njihova uporaba
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
EP1720907B1
(en)
|
2004-02-06 |
2015-04-08 |
MorphoSys AG |
Anti-cd38 human antibodies and uses therefor
|
|
WO2005087812A1
(en)
*
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Multivalent antibody materials and methods for vegf/pdgf family of growth factors
|
|
US7311906B2
(en)
|
2004-04-30 |
2007-12-25 |
Brigham Young University |
Anti-viral activity of an anti-thymidine kinase monoclonal antibody
|
|
CA2504920C
(en)
|
2004-05-14 |
2014-04-01 |
Euroscreen S.A. |
Ligand for g-protein coupled receptor fprl2 and uses thereof
|
|
US8551486B2
(en)
|
2004-05-21 |
2013-10-08 |
Savoy Pharmaceuticals, Inc. |
Monoclonal antibodies to human thymidine kinase to treat cancer
|
|
US7837998B2
(en)
|
2004-05-21 |
2010-11-23 |
Nathaniel Lallatin |
Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
|
|
AU2005250216B2
(en)
|
2004-06-01 |
2009-12-10 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
|
WO2006004663A2
(en)
*
|
2004-06-25 |
2006-01-12 |
Medimmune, Inc. |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
|
EP2322554A1
(en)
|
2004-06-30 |
2011-05-18 |
Domantis Limited |
Composition comprising an anti-TNF-alpha domain antibody for the treatment of rheumatoid arthritis
|
|
JP5143551B2
(ja)
|
2004-07-06 |
2013-02-13 |
バイオレン，インク． |
ユニバーサル抗体のライブラリー
|
|
JP5102028B2
(ja)
|
2004-07-26 |
2012-12-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗ｃｄ１５４抗体
|
|
US7728118B2
(en)
|
2004-09-17 |
2010-06-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
KR20070084069A
(ko)
|
2004-10-08 |
2007-08-24 |
도만티스 리미티드 |
Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
|
|
AU2005306502B2
(en)
|
2004-11-16 |
2012-11-15 |
Humanigen, Inc. |
Immunoglobulin variable region cassette exchange
|
|
EP1841796A2
(en)
|
2004-12-02 |
2007-10-10 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
|
WO2006066089A1
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
|
TW200636066A
(en)
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized antibodies that recognize beta amyloid peptide
|
|
DK2332408T3
(da)
|
2005-02-17 |
2013-12-02 |
Biogen Idec Inc |
Behandling af neurologiske sygdomme
|
|
JP2008532559A
(ja)
|
2005-03-19 |
2008-08-21 |
メディカル リサーチ カウンシル |
ウイルス感染の治療及び予防又は治療及び予防の改善
|
|
CA2607697C
(en)
|
2005-05-10 |
2015-01-06 |
Biogen Idec Ma Inc. |
Treating and evaluating inflammatory disorders
|
|
ME02461B
(me)
|
2005-05-10 |
2017-02-20 |
Incyte Holdings Corp |
Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
|
|
SI3620171T1
(sl)
|
2005-05-18 |
2022-09-30 |
Morphosys Ag |
Protitelesa proti GM-CSF in uporabe zanje
|
|
TW200745162A
(en)
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
CN102441163A
(zh)
|
2005-05-27 |
2012-05-09 |
比奥根艾迪克Ma公司 |
结合tweak的抗体
|
|
WO2006138219A2
(en)
|
2005-06-13 |
2006-12-28 |
Biogen Idec Ma Inc. |
Methods of diagnosis / prognosis of inflammatory conditions
|
|
KR101607288B1
(ko)
|
2005-07-01 |
2016-04-05 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
|
WO2007039256A2
(de)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
CN103554260A
(zh)
|
2005-10-12 |
2014-02-05 |
莫佛塞斯公司 |
特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
|
|
AR058140A1
(es)
*
|
2005-10-24 |
2008-01-23 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
|
EP1945261A4
(en)
|
2005-11-07 |
2010-05-12 |
Scripps Research Inst |
COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
|
|
ATE463512T1
(de)
|
2005-11-09 |
2010-04-15 |
Morphosys Ag |
Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
|
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
|
CN101506236B
(zh)
|
2005-11-30 |
2012-12-12 |
雅培制药有限公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
|
JP2009519011A
(ja)
|
2005-12-01 |
2009-05-14 |
ドマンティス リミテッド |
インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
|
|
EA200801166A1
(ru)
|
2005-12-01 |
2008-12-30 |
Домантис Лимитед |
Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
|
|
CN101351476B
(zh)
|
2005-12-12 |
2013-04-03 |
豪夫迈·罗氏有限公司 |
抗体可变区的糖基化
|
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
|
EP1979378B1
(en)
|
2005-12-20 |
2012-07-25 |
MorphoSys AG |
Novel collection of hcdr3 regions and uses therefor
|
|
EP1984403A2
(en)
|
2006-01-12 |
2008-10-29 |
Alexion Pharmaceuticals, Inc. |
Antibodies to ox-2/cd200 and uses thereof
|
|
US8541177B2
(en)
|
2006-01-13 |
2013-09-24 |
A Chan Holding B.V. |
Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
|
|
DK1973946T3
(da)
|
2006-01-20 |
2015-06-22 |
Cell Signaling Technology Inc |
Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom
|
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
|
WO2007087673A1
(en)
|
2006-02-01 |
2007-08-09 |
Arana Therapeutics Limited |
Domain antibody construct
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
US7833724B2
(en)
*
|
2006-03-20 |
2010-11-16 |
Teva Women's Health, Inc. |
Methods for comparing the immunogenicity of products and uses thereof
|
|
KR20090029184A
(ko)
|
2006-04-07 |
2009-03-20 |
더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
항체 조성물 및 신생물성 질병의 치료 방법
|
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
|
WO2007117657A2
(en)
|
2006-04-07 |
2007-10-18 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
|
US7700339B2
(en)
|
2006-04-14 |
2010-04-20 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
BRPI0710971A2
(pt)
|
2006-04-28 |
2011-05-31 |
Esbatech Ag |
anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
|
|
EP1918302A3
(en)
*
|
2006-05-18 |
2009-11-18 |
AvantGen, Inc. |
Methods for the identification and the isolation of epitope specific antibodies
|
|
EP2034830B1
(en)
*
|
2006-05-25 |
2014-09-03 |
Biogen Idec MA Inc. |
Anti-vla-1 antibody for treating stroke
|
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
CN101563105B
(zh)
|
2006-07-10 |
2013-01-23 |
拜奥根Idec马萨诸塞公司 |
用于抑制smad4-缺陷癌症的组合物和方法
|
|
AP2703A
(en)
|
2006-09-28 |
2013-07-24 |
Macfarlane Burnet Inst For Medical Res & Public Health Ltd |
A method of diagnosis and kit therefor
|
|
AU2007303572A1
(en)
|
2006-10-02 |
2008-04-10 |
Sea Lane Biotechnologies, Llc |
Design and construction of diverse synthetic peptide and polypeptide libraries
|
|
RU2009111138A
(ru)
*
|
2006-10-12 |
2010-11-20 |
Вайет (Us) |
Способы и композиции с уменьшенной опалесценцией
|
|
EP2064315B1
(en)
|
2006-11-03 |
2015-05-13 |
Wyeth LLC |
Glycolysis-inhibiting substances in cell culture
|
|
EP2433635A1
(en)
|
2006-11-10 |
2012-03-28 |
Massachusetts Institute Of Technology |
PAK Modulators
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
EP2114443A4
(en)
|
2006-12-29 |
2011-08-10 |
Abbott Lab |
IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
|
|
JP5675109B2
(ja)
|
2007-02-20 |
2015-02-25 |
アナプティスバイオ インコーポレイティッド |
ライブラリーの生成方法及びその使用
|
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
WO2008112193A1
(en)
|
2007-03-12 |
2008-09-18 |
Dana-Farber Cancer Institute |
Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
|
|
EP2125894B1
(en)
|
2007-03-22 |
2018-12-19 |
Biogen MA Inc. |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
|
CA2688434A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
|
PL2158315T3
(pl)
|
2007-06-25 |
2016-10-31 |
|
Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
|
|
MX2010000979A
(es)
|
2007-07-25 |
2010-03-26 |
Alexion Pharma Inc |
Metodos y composiciones para tratar enfermedad autoinmune.
|
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
|
CN101848998B
(zh)
|
2007-08-30 |
2016-08-03 |
第一三共株式会社 |
抗epha2抗体
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
CA3187687A1
(en)
|
2007-09-14 |
2009-03-19 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
EP3072963B1
(en)
|
2007-10-18 |
2020-04-01 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
|
EP2220500A4
(en)
*
|
2007-11-20 |
2010-12-15 |
3M Innovative Properties Co |
METHOD FOR ANALYZING A BACTERIUM SAMPLE USING A POLYMER DETECTOR CONTAINING DIACETYLENE
|
|
JP5608091B2
(ja)
|
2007-11-26 |
2014-10-15 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
抗メソセリン抗体およびその使用
|
|
UY31504A1
(es)
|
2007-11-30 |
2009-07-17 |
|
Construcciones de union de antigenos
|
|
EP2080770A1
(en)
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinaceous binding molecules comprising purification tags
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
|
DK2281078T3
(en)
|
2008-04-24 |
2015-02-02 |
Dyax Corp |
LIBRARIES OF RE-PACKAGES INCLUDING UNKNOWN HC-CDR1, -CDR2 AND -CDR3 AND UNKNOWN LC-CDR1, -CDR2 AND-CDR3 DESIGNS
|
|
SG176464A1
(en)
|
2008-05-09 |
2011-12-29 |
Agency Science Tech & Res |
Diagnosis and treatment of kawasaki disease
|
|
CN102316897B
(zh)
|
2008-07-08 |
2014-11-05 |
昂考梅德药品有限公司 |
Notch结合剂和拮抗剂及其应用方法
|
|
SG10201805844QA
(en)
|
2008-07-08 |
2018-08-30 |
Incyte Holdings Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
|
CN102159590A
(zh)
|
2008-07-18 |
2011-08-17 |
百时美施贵宝公司 |
Cd28结合为单价的组合物及使用方法
|
|
US8871207B2
(en)
|
2008-07-25 |
2014-10-28 |
Humabs, LLC |
Neutralizing anti-influenza A virus antibodies and uses thereof
|
|
BRPI0911699B8
(pt)
*
|
2008-07-25 |
2023-02-28 |
Inst Res Biomedicine |
vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
|
|
JP5756014B2
(ja)
|
2008-08-08 |
2015-07-29 |
エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） |
がんの診断および治療のためのｖｈｚ
|
|
CN102177178B
(zh)
|
2008-08-14 |
2015-07-01 |
梯瓦制药澳大利亚私人有限公司 |
抗il-12/il-23抗体
|
|
EP2344180A2
(en)
|
2008-09-23 |
2011-07-20 |
Wyeth LLC |
Methods for predicting production of activating signals by cross-linked binding proteins
|
|
EP2350128B1
(en)
*
|
2008-10-22 |
2014-10-01 |
Institute for Research in Biomedicine |
Methods for producing antibodies from plasma cells
|
|
CN102272154A
(zh)
|
2008-10-29 |
2011-12-07 |
惠氏有限责任公司 |
单域抗原结合性分子的纯化方法
|
|
CA2738243C
(en)
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
CA2742968C
(en)
|
2008-11-07 |
2020-06-09 |
Fabrus Llc |
Combinatorial antibody libraries and uses thereof
|
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
|
CN102307897B
(zh)
|
2008-12-05 |
2016-01-20 |
葛兰素集团有限公司 |
选出蛋白酶抗性多肽的方法
|
|
WO2010071923A1
(en)
|
2008-12-22 |
2010-07-01 |
The University Of Melbourne |
Pain treatment
|
|
AU2009329814B2
(en)
|
2008-12-22 |
2015-06-18 |
The University Of Melbourne |
Osteoarthritis treatment
|
|
TWI480050B
(zh)
|
2009-02-10 |
2015-04-11 |
Daiichi Sankyo Co Ltd |
抗－ｍｓｔ１ｒ抗體及其用途
|
|
DK2881402T3
(en)
|
2009-02-12 |
2017-08-28 |
Cell Signaling Technology Inc |
Mutant ROS expression in human liver cancer
|
|
JP2012518400A
(ja)
|
2009-02-24 |
2012-08-16 |
グラクソ グループ リミテッド |
多価および／または複数特異的ｒａｎｋｌ結合性構築物
|
|
CA2744103C
(en)
|
2009-02-24 |
2018-01-02 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Methods for identifying immunobinders of cell-surface antigens
|
|
CA2753332A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
JP2012518398A
(ja)
|
2009-02-24 |
2012-08-16 |
グラクソ グループ リミテッド |
抗原結合性構築物
|
|
EP2406386B1
(en)
*
|
2009-03-10 |
2019-01-23 |
DSM IP Assets B.V. |
Method for improving the yield of a polypeptide
|
|
RS54451B1
(sr)
|
2009-04-29 |
2016-06-30 |
Janssen Biotech, Inc. |
Antagonisti toll-like receptora 3
|
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
US8765916B2
(en)
|
2009-04-29 |
2014-07-01 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
ERG monoclonal antibodies
|
|
CA2762837C
(en)
|
2009-05-20 |
2021-08-03 |
Novimmune S.A. |
Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
|
|
ES2511051T3
(es)
*
|
2009-05-29 |
2014-10-22 |
Morphosys Ag |
Colección de anticuerpos sintéticos para tratar enfermedades
|
|
KR101962476B1
(ko)
|
2009-07-03 |
2019-03-26 |
아비펩 피티와이 리미티트 |
면역성 접합체 및 그 제조방법
|
|
US20120226119A1
(en)
|
2009-07-09 |
2012-09-06 |
Hoffmann-La Roche Inc. |
Vivo tumor vasculature imaging
|
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
|
CA2773564A1
(en)
*
|
2009-09-14 |
2011-03-17 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
|
NZ598791A
(en)
|
2009-10-23 |
2014-05-30 |
Millennium Pharm Inc |
Anti-gcc antibody molecules and related compositions and methods
|
|
CA2780221A1
(en)
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
|
BR112012013734A2
(pt)
|
2009-12-08 |
2017-01-10 |
Abbott Gmbh & Co Kg |
anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
|
|
PT2510012T
(pt)
|
2009-12-09 |
2017-07-13 |
Bayer Pharma AG |
Anticorpos anti-c4.4a e utilizações dos mesmos
|
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
|
US9315581B2
(en)
|
2009-12-23 |
2016-04-19 |
A Vipep Pty Limited |
Immuno-conjugates and methods for producing them
|
|
WO2011082345A2
(en)
|
2009-12-30 |
2011-07-07 |
Brigham Young University |
Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
|
|
US9180186B2
(en)
|
2010-01-11 |
2015-11-10 |
Alexion Pharmaceuticals, Inc. |
Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
|
|
AU2011205316B2
(en)
|
2010-01-13 |
2015-05-28 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
|
EP2354159A1
(en)
|
2010-02-05 |
2011-08-10 |
RWTH Aachen |
CCL17 inhibitors for use in T helper cell-driven diseases
|
|
AU2011215685B2
(en)
|
2010-02-12 |
2015-08-20 |
Oncomed Pharmaceuticals, Inc. |
Methods for identifying and isolating cells expressing a polypeptide
|
|
WO2011103330A2
(en)
|
2010-02-17 |
2011-08-25 |
The Johns Hopkins University |
Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
|
|
KR20230044026A
(ko)
|
2010-02-24 |
2023-03-31 |
이뮤노젠 아이엔씨 |
엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
|
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
|
CN106046159B
(zh)
|
2010-03-12 |
2020-06-16 |
德彪发姆国际有限公司 |
Cd37结合分子及其免疫缀合物
|
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
EP2563813B1
(en)
|
2010-04-30 |
2015-08-26 |
Alexion Pharmaceuticals, Inc. |
Anti-c5a antibodies and methods for using the antibodies
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
EP3336225B1
(en)
|
2010-07-16 |
2020-02-19 |
Adimab, LLC |
Antibody libraries
|
|
CN108314733A
(zh)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
|
US9127057B2
(en)
|
2010-07-20 |
2015-09-08 |
Teva Pharmaceuticals Ausralia Pty Ltd |
Anti-IL-23 heterodimer specific antibodies
|
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
|
CN103260646B
(zh)
|
2010-08-27 |
2016-01-13 |
施特姆森特克斯股份有限公司 |
Notum蛋白调节剂和使用方法
|
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
US9068014B2
(en)
|
2010-09-23 |
2015-06-30 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
|
UY33679A
(es)
|
2010-10-22 |
2012-03-30 |
Esbatech |
Anticuerpos estables y solubles
|
|
WO2012066129A1
(en)
*
|
2010-11-19 |
2012-05-24 |
Morphosys Ag |
A collection and methods for its use
|
|
EP2853542A1
(en)
|
2010-11-24 |
2015-04-01 |
Glaxo Group Limited |
Multispecific antigen binding proteins targeting HGF
|
|
WO2012078813A2
(en)
|
2010-12-08 |
2012-06-14 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
EP2471554A1
(en)
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
|
JP2014506448A
(ja)
|
2011-01-19 |
2014-03-17 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
凝固因子の阻害剤に対する結合タンパク質
|
|
US9669092B2
(en)
|
2011-02-02 |
2017-06-06 |
Emory University |
Antagonism of the VIP signaling pathway
|
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
EP2686016B1
(en)
|
2011-03-14 |
2019-05-01 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
|
WO2012131053A1
(en)
|
2011-03-30 |
2012-10-04 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against tnf-alpha
|
|
US20140010886A1
(en)
|
2011-04-07 |
2014-01-09 |
Georgia Tech Research Corporation |
Compositions comprising saccharide binding moieties and methods for targeted therapy
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
EP2511293A1
(en)
|
2011-04-13 |
2012-10-17 |
LEK Pharmaceuticals d.d. |
A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
|
|
CA2833477A1
(en)
|
2011-04-21 |
2012-10-26 |
Seattle Genetics, Inc. |
Novel binder-drug conjugates (adcs) and their use
|
|
CN103619877B
(zh)
|
2011-04-21 |
2018-01-02 |
加文医学研究所 |
修饰的可变结构域分子及其产生和使用方法b
|
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
|
EP2726504A1
(en)
|
2011-05-27 |
2014-05-07 |
Dutalys |
Antibodies with improved folding stability
|
|
SI2726510T1
(sl)
|
2011-05-27 |
2023-06-30 |
F. Hoffmann - La Roche Ag |
Dvojno ciljanje
|
|
US20140255405A1
(en)
|
2011-05-27 |
2014-09-11 |
Dutalys |
Removal of Monomeric Targets
|
|
EP2530089A1
(en)
|
2011-06-03 |
2012-12-05 |
Bayer Pharma Aktiengesellschaft |
Neutralising prolactin receptor antibody Mat3 and its therapeutical use
|
|
ES2828482T3
(es)
|
2011-06-13 |
2021-05-26 |
Csl Ltd |
Anticuerpos contra el g-csfr y su uso
|
|
ES2552427T3
(es)
|
2011-06-16 |
2015-11-27 |
Universitätsklinikum Freiburg |
Composición farmacéutica con anticuerpos contra catalasa y superóxido dismutasa
|
|
CN106167526A
(zh)
|
2011-07-15 |
2016-11-30 |
昂考梅德药品有限公司 |
Rspo结合剂和其应用
|
|
AU2012285875B2
(en)
|
2011-07-18 |
2016-11-10 |
Morphosys Ag |
Use of c-Fms antagonists
|
|
HUE044089T2
(hu)
|
2011-07-18 |
2019-09-30 |
Inst Res Biomedicine |
Neutralizáló anti-influenza A antitestek és alkalmazásaik
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
MX362457B
(es)
|
2011-09-12 |
2019-01-18 |
Janssen Biotech Inc |
Antagonistas del receptor tipo toll 3.
|
|
AU2012311492A1
(en)
|
2011-09-23 |
2014-03-06 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5T4 and CD3
|
|
DK3485903T5
(da)
|
2011-09-23 |
2024-09-02 |
Mereo Biopharma 5 Inc |
Vegf/dll4-bindende midler og anvendelser deraf
|
|
JP2014531210A
(ja)
|
2011-09-30 |
2014-11-27 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
ＴＬ１ａに対する抗体およびその使用
|
|
CN103906865B
(zh)
|
2011-10-07 |
2017-12-08 |
拜斯科医疗有限公司 |
结构化多肽特异性的调控
|
|
HRP20180776T1
(hr)
|
2011-10-19 |
2018-08-10 |
Morphosys Ag |
Antagonisti il17c za liječenje upalnih poremećaja
|
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
|
KR102096224B1
(ko)
|
2011-10-28 |
2020-04-03 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
폴리펩티드 구축물 및 이의 용도
|
|
WO2013071233A1
(en)
|
2011-11-10 |
2013-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for detecting infectious agents and a novel virus detected thereby
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
US9220775B2
(en)
|
2011-11-23 |
2015-12-29 |
Medimmune Llc |
Binding molecules specific for HER3 and uses thereof
|
|
MX2014007121A
(es)
|
2011-12-14 |
2014-09-04 |
Seattle Genetics Inc |
Nuevos conjugados de principio activo-ligante (adc) y su uso.
|
|
SG11201404263TA
(en)
|
2012-01-27 |
2014-08-28 |
Abbvie Deutschland |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
AU2013221635B2
(en)
|
2012-02-16 |
2017-12-07 |
Santarus, Inc. |
Anti-VLA1 (CD49a) antibody pharmaceutical compositions
|
|
ES2812849T3
(es)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
|
|
MX353382B
(es)
|
2012-03-01 |
2018-01-10 |
Amgen Res Munich Gmbh |
Moleculas de union polipeptido de larga duracion.
|
|
US9708388B2
(en)
|
2012-04-11 |
2017-07-18 |
Hoffmann-La Roche Inc. |
Antibody light chains
|
|
DK2838998T3
(en)
|
2012-04-18 |
2018-01-15 |
Cell Signaling Technology Inc |
EGFR AND ROS1 IN CANCER
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
SG10201609322QA
(en)
|
2012-05-10 |
2017-01-27 |
Bayer Pharma AG |
Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
|
|
EP2858673A4
(en)
|
2012-06-06 |
2016-06-22 |
Oncomed Pharm Inc |
BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
|
|
CA2876165C
(en)
|
2012-06-25 |
2021-06-15 |
Emory University |
Particle-nucleic acid conjugates and therapeutic uses related thereto
|
|
JP6293147B2
(ja)
|
2012-08-31 |
2018-03-14 |
イミュノジェン， インコーポレイテッド |
葉酸受容体１の検出のための診断分析およびキット
|
|
CN104902923A
(zh)
|
2012-11-05 |
2015-09-09 |
建新公司 |
用于治疗蛋白质病的组合物和方法
|
|
MX363407B
(es)
|
2012-12-10 |
2019-03-22 |
Biogen Ma Inc |
Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
|
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
|
PT2951208T
(pt)
|
2013-02-01 |
2019-12-30 |
Univ California |
Anticorpos anti-cd83 e sua utilização
|
|
SG11201505762XA
(en)
|
2013-02-07 |
2015-08-28 |
Csl Ltd |
Il-11r binding proteins and uses thereof
|
|
ES2731681T3
(es)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
|
|
CN105392801A
(zh)
|
2013-03-15 |
2016-03-09 |
比奥根Ma公司 |
使用抗αvβ5抗体治疗和预防急性肾损伤
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
|
JP6671276B2
(ja)
|
2013-03-27 |
2020-03-25 |
セダーズ−シナイ メディカル センター |
Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
|
|
GB201306623D0
(en)
|
2013-04-11 |
2013-05-29 |
Bicycle Therapeutics Ltd |
Modulation of structured polypeptide specificity
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
EP2992013B1
(en)
|
2013-04-29 |
2019-12-04 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
MX2015016814A
(es)
|
2013-06-14 |
2016-08-08 |
Bayer Pharma AG |
Anticuerpo anti-tweakr y sus usos.
|
|
EP4105236A1
(en)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
|
|
KR102062784B1
(ko)
|
2013-07-23 |
2020-01-07 |
바이오콘 리미티드 |
단백질 내 푸코실화 수준을 제어하는 방법
|
|
EP3038634A4
(en)
|
2013-08-28 |
2017-10-11 |
AbbVie Stemcentrx LLC |
Novel sez6 modulators and methods of use
|
|
AU2014312215B2
(en)
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
|
LT3038650T
(lt)
|
2013-08-30 |
2021-09-10 |
Immunogen, Inc. |
Antikūnai ir foliatų receptoriaus 1 nustatymo testai
|
|
EP4215209A1
(en)
|
2013-09-02 |
2023-07-26 |
The University of Melbourne |
A method of treatment
|
|
CN113667013B
(zh)
|
2013-10-02 |
2024-04-09 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
|
WO2015054400A2
(en)
|
2013-10-08 |
2015-04-16 |
Immunogen, Inc. |
Anti-folr1 immunoconjugate dosing regimens
|
|
KR102339724B1
(ko)
|
2013-11-28 |
2021-12-17 |
씨에스엘 리미티드 |
신장병증의 치료 방법
|
|
US9309314B2
(en)
|
2013-12-03 |
2016-04-12 |
Agency For Science, Technology And Research (A*Star) |
Polypeptides, nucleic acids and uses thereof
|
|
EP3080158A4
(en)
|
2013-12-09 |
2018-03-21 |
Adimab, LLC |
Polyclonal mixtures of antibodies, and methods of making and using them
|
|
US9644023B2
(en)
|
2013-12-09 |
2017-05-09 |
New York University |
Compositions and methods for phagocyte delivery of anti-staphylococcal agents
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
DK3082860T3
(da)
|
2013-12-18 |
2021-01-25 |
Csl Ltd |
Fremgangsmåde til behandling af sår
|
|
CA2934617A1
(en)
|
2013-12-23 |
2015-07-02 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
|
|
SG11201605745VA
(en)
|
2014-01-14 |
2016-08-30 |
Wisconsin Med College Inc |
Targeting clptm1l for treatment and prevention of cancer
|
|
EP3107576A4
(en)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
EP3126384B1
(en)
|
2014-04-01 |
2020-12-02 |
Adimab, LLC |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
SG10201913627TA
(en)
|
2014-04-08 |
2020-03-30 |
Boston Pharmaceuticals Inc |
Binding molecules specific for il-21 and uses thereof
|
|
HK1232127A1
(zh)
|
2014-04-11 |
2018-01-05 |
Medimmune, Llc |
双特异性her2抗体
|
|
JP2017518737A
(ja)
|
2014-04-21 |
2017-07-13 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
US9903868B2
(en)
|
2014-05-16 |
2018-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for the detection and quantitation of biomarkers
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
CA2954780A1
(en)
|
2014-07-15 |
2016-01-21 |
Medimmune, Llc |
Neutralizing anti-influenza b antibodies and uses thereof
|
|
CA2952540C
(en)
|
2014-07-31 |
2022-06-21 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
AU2015294834B2
(en)
|
2014-07-31 |
2021-04-29 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
EP3209697A4
(en)
|
2014-10-23 |
2018-05-30 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
|
CA2965170A1
(en)
|
2014-10-23 |
2016-04-28 |
Dendrocyte Biotech Pty Ltd |
Cd83 binding proteins and uses thereof
|
|
RU2708459C2
(ru)
|
2014-10-29 |
2019-12-09 |
БайсиклРД Лимитед |
Бициклические пептидные лиганды, специфичные для мт1-ммр
|
|
UA125637C2
(uk)
|
2014-10-29 |
2022-05-11 |
Тева Фармасьютікалз Острейліа Пті Лтд |
ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
|
|
CN112778418B
(zh)
|
2014-11-10 |
2025-04-22 |
免疫医疗有限公司 |
对cd73具有特异性的结合分子及其用途
|
|
HK1246304A1
(zh)
|
2014-11-11 |
2018-09-07 |
Medimmune Limited |
包含抗cd73抗体和a2a受体抑制剂的治疗组合及其用途
|
|
US11033637B2
(en)
|
2014-11-21 |
2021-06-15 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
|
KR102657306B1
(ko)
|
2014-12-08 |
2024-04-12 |
버그 엘엘씨 |
전립선암의 진단 및 치료에서 필라민을 포함하는 마커의 용도
|
|
US10485880B2
(en)
|
2014-12-15 |
2019-11-26 |
Bayer Pharma Aktiengesellschaft |
Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
|
|
US10940212B2
(en)
|
2014-12-19 |
2021-03-09 |
Monash University |
IL-21 agonist antibodies and methods of treatment using same
|
|
WO2016126488A1
(en)
|
2015-02-02 |
2016-08-11 |
Sea Lane Biotechnologies, Llc |
Anti-surrogate light chain antibodies
|
|
CN107207606A
(zh)
|
2015-02-02 |
2017-09-26 |
乔治.鲍尔 |
结合并抑制过氧化氢酶和/或超氧化物歧化酶的抗原结合构建体即单域vhh片段以及用于肿瘤疗法的含有它们的药物组合物
|
|
RS59878B1
(sr)
|
2015-03-23 |
2020-03-31 |
Bayer Pharma AG |
Anti-ceacam6 antitela i njihova primena
|
|
US11136401B2
(en)
|
2015-03-27 |
2021-10-05 |
University Of Southern California |
Car t-cell therapy directed to LHR for the treatment of solid tumors
|
|
HUE053097T2
(hu)
|
2015-03-31 |
2021-06-28 |
Medimmune Ltd |
Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására
|
|
WO2016164708A1
(en)
|
2015-04-10 |
2016-10-13 |
Adimab, Llc |
Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
|
AR104309A1
(es)
|
2015-04-17 |
2017-07-12 |
Bayer Pharma AG |
Construcciones de anticuerpos biespecíficos para cdh3 y cd3
|
|
US20180104331A1
(en)
|
2015-05-11 |
2018-04-19 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
|
US10900975B2
(en)
|
2015-05-12 |
2021-01-26 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Systems and methods of epitope binning and antibody profiling
|
|
EP3095465A1
(en)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Combination of fgfr4-inhibitor and bile acid sequestrant
|
|
HUE056407T2
(hu)
|
2015-06-01 |
2022-02-28 |
Medimmune Llc |
Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
|
|
AU2016270474A1
(en)
|
2015-06-04 |
2018-01-04 |
University Of Southern California |
Lym-1 and Lym-2 targeted CAR cell immunotherapy
|
|
JP6971858B2
(ja)
|
2015-06-22 |
2021-11-24 |
バイエル ファーマ アクチエンゲゼルシャフト |
酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
|
|
CN108025086A
(zh)
|
2015-06-23 |
2018-05-11 |
拜耳制药股份公司 |
Ksp抑制剂与抗b7h3抗体的抗体-活性物质缀合物(adc)
|
|
EP3313521A1
(de)
|
2015-06-23 |
2018-05-02 |
Bayer Pharma Aktiengesellschaft |
Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
|
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
|
LT3313884T
(lt)
|
2015-06-29 |
2021-03-10 |
Immunogen, Inc. |
Anti-cd123 antikūnai, konjugatai ir jų dariniai
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
EP3349796A4
(en)
|
2015-09-17 |
2019-05-29 |
ImmunoGen, Inc. |
THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES
|
|
CA2999037A1
(en)
|
2015-09-23 |
2017-03-30 |
Cytoimmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CN114057885A
(zh)
|
2015-10-02 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
|
|
US10604566B2
(en)
|
2015-10-05 |
2020-03-31 |
Galapagos Nv |
Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
|
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
|
ITUB20155272A1
(it)
|
2015-11-02 |
2017-05-02 |
Scuola Normale Superiore |
Intracellular antibody
|
|
PT3374398T
(pt)
|
2015-11-10 |
2020-06-16 |
Medimmune Llc |
Moléculas de ligação específicas para asct2 e suas utilizações
|
|
BR112018010766A8
(pt)
|
2015-11-27 |
2019-02-26 |
Csl Ltd |
proteínas de ligação ao cd131 e usos das mesmas
|
|
US20190015509A1
(en)
|
2016-01-13 |
2019-01-17 |
Medimmune, Llc |
Method of treating influenza a
|
|
IL260920B
(en)
|
2016-02-03 |
2022-09-01 |
Amgen Res Munich Gmbh |
Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
KR102866147B1
(ko)
|
2016-03-10 |
2025-09-30 |
악셀레론 파마 인코포레이티드 |
액티빈 타입 2 수용체 결합 단백질 및 이의 용도
|
|
MX2018010771A
(es)
|
2016-03-10 |
2019-05-15 |
Viela Bio Inc |
Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
|
|
BR112018068461A2
(pt)
|
2016-03-15 |
2019-01-22 |
Mersana Therapeutics Inc |
conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
|
|
US11186872B2
(en)
|
2016-03-17 |
2021-11-30 |
Cedars-Sinai Medical Center |
Methods of diagnosing inflammatory bowel disease through RNASET2
|
|
JP7251981B2
(ja)
|
2016-03-24 |
2023-04-04 |
バイエル ファーマ アクチエンゲゼルシャフト |
酵素開裂基を有する細胞毒性活性剤のプロドラッグ
|
|
EP3436461B1
(en)
|
2016-03-28 |
2023-11-01 |
Incyte Corporation |
Pyrrolotriazine compounds as tam inhibitors
|
|
US10765724B2
(en)
|
2016-03-29 |
2020-09-08 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
KR20220080015A
(ko)
|
2016-04-22 |
2022-06-14 |
악셀레론 파마 인코포레이티드 |
Alk7 결합 단백질 및 이들의 용도
|
|
WO2017205101A1
(en)
|
2016-05-27 |
2017-11-30 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
MY194619A
(en)
|
2016-06-02 |
2022-12-07 |
Abbvie Inc |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
|
CN109310781B
(zh)
|
2016-06-15 |
2024-06-18 |
拜耳制药股份公司 |
具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
|
|
AU2017292752B2
(en)
|
2016-07-06 |
2023-07-27 |
Celgene Corporation |
Antibodies with low immunogenicity and uses thereof
|
|
WO2018009834A1
(en)
|
2016-07-07 |
2018-01-11 |
Berg Llc |
Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
|
|
US11618784B2
(en)
|
2016-07-19 |
2023-04-04 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD47 combination therapy
|
|
WO2018022479A1
(en)
|
2016-07-25 |
2018-02-01 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
|
US11447542B2
(en)
|
2016-08-05 |
2022-09-20 |
Medimmune, Llc |
Anti-O2 antibodies and uses thereof
|
|
CN106279414A
(zh)
*
|
2016-08-31 |
2017-01-04 |
天津医科大学总医院 |
人源性抗胰淀素抗体及其制备方法
|
|
JP7217225B2
(ja)
|
2016-09-01 |
2023-02-02 |
フォルシュングスフェアバント ベルリン エー．ベー． |
アルケンホスホンアミデートまたはアルキンホスホンアミデートとの化学選択的チオールコンジュゲーション
|
|
WO2018041740A1
(en)
|
2016-09-01 |
2018-03-08 |
Bayer Pharma Aktiengesellschaft |
Non-covalent display system using fimgt/dsf
|
|
WO2018050902A2
(en)
|
2016-09-15 |
2018-03-22 |
Quadrucept Bio Limited |
Multimers, tetramers & octamers
|
|
CA3034105A1
(en)
|
2016-09-23 |
2018-03-29 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
MA46366A
(fr)
|
2016-09-30 |
2019-08-07 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
|
|
WO2018075408A1
(en)
|
2016-10-17 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
|
|
KR20190064636A
(ko)
|
2016-10-19 |
2019-06-10 |
메디뮨 엘엘씨 |
항-o1 항체 및 이의 용도
|
|
KR20190082815A
(ko)
|
2016-10-26 |
2019-07-10 |
세다르스-신나이 메디칼 센터 |
중화 항-tl1a 단일 클론 항체
|
|
CA3044244A1
(en)
|
2016-11-16 |
2018-05-24 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-il23 specific antibody
|
|
CN110662770A
(zh)
|
2016-11-23 |
2020-01-07 |
比奥维拉迪维治疗股份有限公司 |
结合凝血因子ix和凝血因子x的双特异性抗体
|
|
WO2018102594A1
(en)
|
2016-12-01 |
2018-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods of treating solid tumors with anti-cd200 antibodies
|
|
EP3555625A1
(en)
|
2016-12-16 |
2019-10-23 |
Merck Patent GmbH |
Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
|
|
GB201621806D0
(en)
|
2016-12-21 |
2017-02-01 |
Philogen Spa |
Immunocytokines with progressive activation mechanism
|
|
US12059472B2
(en)
|
2016-12-21 |
2024-08-13 |
Bayer Aktiengesellschaft |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
|
US11660351B2
(en)
|
2016-12-21 |
2023-05-30 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (ADCs) having enzymatically cleavable groups
|
|
WO2018114804A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
AR111211A1
(es)
|
2017-02-06 |
2019-06-19 |
Australian Meat & Live Stock |
Composiciones inmunoestimulantes y sus usos
|
|
WO2018178936A1
(en)
|
2017-03-30 |
2018-10-04 |
Duke University |
Radiolabeled biomolecules and their use
|
|
WO2018192974A1
(en)
|
2017-04-18 |
2018-10-25 |
Université Libre de Bruxelles |
Biomarkers and targets for proliferative diseases
|
|
GB201706477D0
(en)
|
2017-04-24 |
2017-06-07 |
Bicycle Therapeutics Ltd |
Modification of polypeptides
|
|
TWI868050B
(zh)
|
2017-05-05 |
2025-01-01 |
美商安進公司 |
用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
|
|
EP3401328A1
(en)
|
2017-05-10 |
2018-11-14 |
Bayer Pharma Aktiengesellschaft |
One step antibody humanization by golden gate based germline framework region shuffling
|
|
EP3403649A1
(en)
|
2017-05-16 |
2018-11-21 |
Bayer Pharma Aktiengesellschaft |
Inhibitors and antagonists of gpr84 for the treatment of endometriosis
|
|
CN110753703B
(zh)
|
2017-05-23 |
2024-04-09 |
德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） |
新的cd73抗体、其制备和用途
|
|
EP3406253A1
(en)
|
2017-05-24 |
2018-11-28 |
Bayer Aktiengesellschaft |
Inhibitors and antagonists of human pycr1
|
|
MA49255A
(fr)
|
2017-06-05 |
2020-04-15 |
Numab Therapeutics AG |
Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa
|
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
IL322943A
(en)
|
2017-07-11 |
2025-10-01 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and their use
|
|
FI3658184T3
(fi)
|
2017-07-27 |
2023-11-30 |
Alexion Pharma Inc |
Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
IL273202B2
(en)
|
2017-09-11 |
2024-08-01 |
Univ Monash |
Binding proteins to the human thrombin receptor, par4
|
|
EP3459968A1
(en)
*
|
2017-09-20 |
2019-03-27 |
Numab Innovation AG |
Novel stable antibody variable domain framework combinations
|
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
|
|
MY208007A
(en)
|
2017-09-27 |
2025-04-04 |
Incyte Corp |
Salts of pyrrolotriazine derivatives useful as tam inhibitors
|
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
|
WO2019081456A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
|
|
JP7518764B2
(ja)
|
2017-10-26 |
2024-07-18 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
MA50580A
(fr)
|
2017-11-06 |
2020-09-16 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23
|
|
US11591385B2
(en)
|
2017-11-09 |
2023-02-28 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
US20210179721A1
(en)
|
2017-11-29 |
2021-06-17 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
|
CN111315780A
(zh)
|
2017-12-11 |
2020-06-19 |
安进公司 |
双特异性抗体产品的连续制造工艺
|
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
JP7542257B2
(ja)
|
2018-01-25 |
2024-08-30 |
エイシーエム バイオラブズ プライベート リミテッド |
可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
|
|
CA3089754A1
(en)
|
2018-01-31 |
2019-08-08 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
|
US11512127B2
(en)
|
2018-02-14 |
2022-11-29 |
Viela Bio, Inc. |
Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
|
|
JP2021514953A
(ja)
|
2018-02-23 |
2021-06-17 |
バイスクルテクス・リミテッド |
多量体二環式ペプチドリガンド
|
|
JP7474709B2
(ja)
|
2018-02-27 |
2024-04-25 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
|
|
US20190269757A1
(en)
|
2018-03-05 |
2019-09-05 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
|
AU2019232602B2
(en)
|
2018-03-07 |
2025-03-27 |
Forschungsverbund Berlin E.V. |
Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
|
|
KR102495666B1
(ko)
|
2018-03-14 |
2023-02-06 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
|
KR102879521B1
(ko)
|
2018-03-22 |
2025-11-03 |
서피스 온콜로지, 엘엘씨 |
항-il-27 항체 및 이의 용도
|
|
WO2019178645A1
(en)
|
2018-03-23 |
2019-09-26 |
Csl Limited |
Method of treating asthma
|
|
EP3768701B1
(en)
|
2018-03-23 |
2023-08-02 |
Université Libre de Bruxelles |
Wnt signaling agonist molecules
|
|
EP3775900A1
(en)
|
2018-03-26 |
2021-02-17 |
Alexion Pharmaceuticals, Inc. |
High throughput method for measuring the protease activity of complement c3 convertase
|
|
WO2019185515A1
(en)
|
2018-03-26 |
2019-10-03 |
Glycanostics S.R.O. |
Means and methods for glycoprofiling of a protein
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
US11471506B2
(en)
|
2018-04-23 |
2022-10-18 |
Emory University |
VIP antagonists and uses in treating cancer
|
|
CN112585165B8
(zh)
|
2018-04-25 |
2025-02-14 |
普罗米修斯生物科学公司 |
优化的抗tl1a抗体
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
TW202003580A
(zh)
|
2018-05-21 |
2020-01-16 |
美商坎伯斯治療有限責任公司 |
用於增強nk細胞對標靶細胞之殺死之組合物及方法
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
WO2019231983A1
(en)
|
2018-05-31 |
2019-12-05 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
KR102115300B1
(ko)
|
2018-06-01 |
2020-05-26 |
재단법인 목암생명과학연구소 |
항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
|
|
JP7577542B2
(ja)
|
2018-06-04 |
2024-11-05 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
|
|
WO2019233810A1
(en)
|
2018-06-04 |
2019-12-12 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
|
MX2020013832A
(es)
|
2018-06-18 |
2021-03-25 |
Bayer Ag |
Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado.
|
|
EP4349411A3
(en)
|
2018-06-20 |
2024-06-19 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
|
US12129298B2
(en)
|
2018-06-21 |
2024-10-29 |
Daiichi Sankyo Company, Limited |
Compositions including CD3 antigen binding fragments and uses thereof
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
JP7538723B2
(ja)
|
2018-06-28 |
2024-08-22 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗ｃ５抗体の産生方法
|
|
AR117600A1
(es)
|
2018-06-29 |
2021-08-18 |
Incyte Corp |
Formulaciones de un inhibidor de axl / mer
|
|
PE20210462A1
(es)
|
2018-07-05 |
2021-03-08 |
Bayer Ag |
METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
JP7634474B2
(ja)
|
2018-07-18 |
2025-02-21 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
|
|
EP3830121A1
(en)
|
2018-07-30 |
2021-06-09 |
Amgen Research (Munich) GmbH |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
UA129980C2
(uk)
|
2018-08-03 |
2025-10-01 |
Емджен Рісерч (Мюнік) Ґмбг |
Конструкція на основі антитіл для зв'язування cldn18.2 і cd3
|
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
US12460004B2
(en)
|
2018-08-09 |
2025-11-04 |
Compass Therapeutics Llc |
Antibodies that bind CD277 and uses thereof
|
|
JP2021534779A
(ja)
|
2018-08-27 |
2021-12-16 |
アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク |
抗体構築物がプレロードされた凍結保存ｎｋ細胞
|
|
CN112996539A
(zh)
|
2018-09-12 |
2021-06-18 |
Acm生物实验室私人有限公司 |
包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
|
|
SMT202300262T1
(it)
|
2018-09-24 |
2023-09-06 |
Janssen Biotech Inc |
Metodo sicuro ed efficace di trattamento della colite ulcerosa con anticorpo anti-il12/il23
|
|
SG11202103275YA
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc |
Downstream processing of bispecific antibody constructs
|
|
US12129305B2
(en)
|
2018-10-25 |
2024-10-29 |
The Medical College Of Wisconsin, Inc. |
Targeting CLPTM1L for treatment and prevention of cancer
|
|
AU2019370295A1
(en)
|
2018-10-30 |
2021-06-03 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
AU2019383017A1
(en)
|
2018-11-20 |
2021-06-03 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
|
|
EP3883961A1
(en)
|
2018-11-20 |
2021-09-29 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
|
EP3894440A4
(en)
|
2018-12-13 |
2022-09-07 |
Surface Oncology, Inc. |
ANTI-IL-27 ANTIBODIES AND THEIR USES
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
EP3897722A4
(en)
|
2018-12-18 |
2022-09-14 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE METHOD OF TREATMENT OF LUPUS WITH ANTI-IL12/IL23 ANTIBODIES
|
|
EP3897849A1
(en)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
JP7520848B2
(ja)
|
2018-12-28 |
2024-07-23 |
スパークス・セラピューティクス・インコーポレイテッド |
癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
|
|
CA3127072A1
(en)
|
2019-01-16 |
2020-07-23 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human cd137 and uses thereof
|
|
EP3911675A1
(en)
|
2019-01-17 |
2021-11-24 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020159445A1
(en)
|
2019-01-31 |
2020-08-06 |
Agency For Science, Technology And Research |
Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
|
|
CA3128793C
(en)
|
2019-02-18 |
2023-02-28 |
Atb Therapeutics |
Method of producing a binder-toxin fusion protein in a plant cell or a whole plant
|
|
KR20210152472A
(ko)
|
2019-03-11 |
2021-12-15 |
메모리얼 슬로안 케터링 캔서 센터 |
Cd22 항체 및 이를 사용하는 방법
|
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
|
CA3133381A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
|
CN113825769A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于产生抗tnf抗体组合物的方法
|
|
WO2020183271A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
|
EP3941934A4
(en)
|
2019-03-18 |
2022-12-07 |
Janssen Biotech, Inc. |
METHODS OF TREATMENT OF PSORIASIS IN CHILDREN WITH ANTI-IL12/IL23 ANTIBODIES
|
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
|
US20220249458A1
(en)
|
2019-04-04 |
2022-08-11 |
Bayer Aktiengesellschaft |
Agonists Of Adiponectin
|
|
US20220204610A1
(en)
|
2019-04-09 |
2022-06-30 |
New York Society For The Relief Of The Ruptured And Crippled, Maintaing Hospital For Special Surgery |
Protein binders for irhom2
|
|
WO2020223576A1
(en)
|
2019-04-30 |
2020-11-05 |
Chondrial Therapeutics, Inc. |
Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
|
|
KR20220012883A
(ko)
|
2019-05-23 |
2022-02-04 |
얀센 바이오테크 인코포레이티드 |
Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
|
|
CN114025796A
(zh)
|
2019-06-04 |
2022-02-08 |
詹森生物科技公司 |
用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法
|
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
JP2022543062A
(ja)
|
2019-08-01 |
2022-10-07 |
インサイト・コーポレイション |
Ｉｄｏ阻害剤の投与レジメン
|
|
MX2022002981A
(es)
|
2019-09-10 |
2022-04-06 |
Amgen Inc |
Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
|
|
US11655303B2
(en)
|
2019-09-16 |
2023-05-23 |
Surface Oncology, Inc. |
Anti-CD39 antibody compositions and methods
|
|
BR112022004302A2
(pt)
|
2019-09-25 |
2022-06-21 |
Surface Oncology Inc |
Anticorpos anti-il-27 e usos dos mesmos
|
|
EP4037699A1
(en)
|
2019-09-30 |
2022-08-10 |
SciRhom GmbH |
Protein binders to irhom2 epitopes
|
|
GB201914233D0
(en)
|
2019-10-02 |
2019-11-13 |
Bicyclerd Ltd |
Phage cyclisation assay
|
|
MX2022004942A
(es)
|
2019-10-24 |
2022-07-27 |
Prometheus Biosciences Inc |
Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
|
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
US20230034584A1
(en)
|
2019-12-04 |
2023-02-02 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
|
WO2021123173A1
(en)
|
2019-12-20 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Il-37 fusion proteins and uses thereof
|
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
EP4081554A1
(en)
|
2019-12-27 |
2022-11-02 |
Affimed GmbH |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
|
JP7657230B2
(ja)
|
2020-01-03 |
2025-04-04 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ及びｐｄ－１／ｐｄ－ｌ１阻害剤を含む併用療法
|
|
EP4087607A1
(en)
|
2020-01-06 |
2022-11-16 |
Vaccinex, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
EP4093771A1
(en)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
EP4114401A1
(en)
|
2020-03-06 |
2023-01-11 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
|
JP7750852B2
(ja)
|
2020-03-19 |
2025-10-07 |
アムジエン・インコーポレーテツド |
ムチン１７に対する抗体及びその使用
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
KR20230006551A
(ko)
|
2020-05-05 |
2023-01-10 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 크론병을 치료하는 방법
|
|
MX2022014636A
(es)
|
2020-05-19 |
2023-02-23 |
Amgen Inc |
Construcciones de unión a mageb2.
|
|
BR112022023489A2
(pt)
|
2020-05-21 |
2023-03-14 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
|
MX2022014902A
(es)
|
2020-05-29 |
2023-01-04 |
Amgen Inc |
Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3.
|
|
EP4178616A4
(en)
|
2020-07-13 |
2024-07-24 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY
|
|
WO2022024065A1
(en)
|
2020-07-30 |
2022-02-03 |
Janssen Biotech, Inc. |
Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
|
|
CN116390947A
(zh)
|
2020-08-17 |
2023-07-04 |
Atb治疗公司 |
包含核糖体毒素或RNAse的重组免疫毒素
|
|
WO2022047359A1
(en)
|
2020-08-31 |
2022-03-03 |
Berg Llc |
Protein biomarkers for pancreatic cancer
|
|
CR20230146A
(es)
|
2020-09-11 |
2023-06-07 |
Medimmune Ltd |
Moléculas de unión a b7-h4 terapéuticas
|
|
US20240302348A1
(en)
|
2020-09-12 |
2024-09-12 |
Medimmune Limited |
A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy
|
|
US20240010750A1
(en)
|
2020-09-15 |
2024-01-11 |
Bayer Aktiengesellschaft |
Novel anti-a2ap antibodies and uses thereof
|
|
AU2021357841A1
(en)
|
2020-10-08 |
2023-06-15 |
Affimed Gmbh |
Trispecific binders
|
|
WO2022096704A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
CN116635421A
(zh)
|
2020-11-06 |
2023-08-22 |
安进公司 |
与cd3结合的多肽构建体
|
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
|
TW202233679A
(zh)
|
2020-11-06 |
2022-09-01 |
德商安美基研究（慕尼黑）公司 |
選擇性地與cldn6和cd3結合的多肽構建體
|
|
CA3203587A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
|
TW202241441A
(zh)
|
2020-12-29 |
2022-11-01 |
美商英塞特公司 |
包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
|
|
AU2022208361A1
(en)
|
2021-01-13 |
2023-07-27 |
Daiichi Sankyo Company, Limited |
Anti-dll3 antibody-drug conjugate
|
|
MX2023008261A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
|
|
AU2022225064A1
(en)
|
2021-02-26 |
2023-08-10 |
Bayer Aktiengesellschaft |
Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
CA3208070A1
(en)
|
2021-03-01 |
2022-09-09 |
Matthias Schneider |
Humanized antibodies against irhom2
|
|
AU2022232007A1
(en)
|
2021-03-12 |
2023-10-26 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
|
WO2022190033A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
|
WO2022195028A2
(en)
|
2021-03-18 |
2022-09-22 |
Medimmune Limited |
Therapeutic binding molecules
|
|
CA3213771A1
(en)
|
2021-03-29 |
2022-10-06 |
Scirhom Gmbh |
Methods of treatment using protein binders to irhom2 epitopes
|
|
EP4314047A1
(en)
|
2021-03-30 |
2024-02-07 |
Bayer Aktiengesellschaft |
Anti-sema3a antibodies and uses thereof
|
|
CA3214833A1
(en)
|
2021-04-06 |
2022-10-13 |
Bpgbio, Inc. |
Protein markers for the prognosis of breast cancer progression
|
|
WO2022216841A1
(en)
|
2021-04-06 |
2022-10-13 |
Berg Llc |
Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
|
|
EP4320441A1
(en)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
|
|
WO2022216795A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Abterra Biosciences, Inc. |
Method for antibody identification from protein mixtures
|
|
JP2024518710A
(ja)
|
2021-04-12 |
2024-05-02 |
エイシーエム バイオラブズ プライベート リミテッド |
可溶性封入ポリヌクレオチドとイオン化可能脂質とを含むポリマーソームならびにその作製および使用方法
|
|
CN117545511A
(zh)
|
2021-04-23 |
2024-02-09 |
柏林合作研究学会 |
与不饱和磷(v)化合物的硫醇偶联
|
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
KR20240005809A
(ko)
|
2021-05-07 |
2024-01-12 |
서피스 온콜로지, 엘엘씨 |
항-il-27 항체 및 이의 용도
|
|
CN117916260A
(zh)
|
2021-07-09 |
2024-04-19 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
|
IL310773A
(en)
|
2021-09-02 |
2024-04-01 |
Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts |
Anti-CECAM6 antibodies with reduced side effects
|
|
UY39967A
(es)
|
2021-10-06 |
2023-05-15 |
Immatics Biotechnologies Gmbh |
Indicaciones para los aglutinantes anti-PRAME
|
|
EP4423126A1
(en)
|
2021-10-29 |
2024-09-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
EP4426439A1
(en)
|
2021-11-03 |
2024-09-11 |
Affimed GmbH |
Bispecific cd16a binders
|
|
CN119798440A
(zh)
|
2021-11-03 |
2025-04-11 |
同润生物医药(上海)有限公司 |
新型抗l1cam抗体
|
|
EP4448108A1
(en)
|
2021-11-08 |
2024-10-23 |
Immatics Biotechnologies GmbH |
Adoptive cell therapy combination treatment and compositions thereof
|
|
IL312677A
(en)
|
2021-11-09 |
2024-07-01 |
Tubulis Gmbh |
Conjugates including phosphorus (V) and a camptothecin component
|
|
IL312675A
(en)
|
2021-11-09 |
2024-07-01 |
Tubulis Gmbh |
Conjugates involving phosphorus (V) and a drug component
|
|
AU2022388887A1
(en)
|
2021-11-15 |
2024-07-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
EP4183800A1
(en)
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Novel sars-cov-2 neutralizing antibodies
|
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
|
KR20240131370A
(ko)
|
2021-12-22 |
2024-08-30 |
인사이트 코포레이션 |
항-cd19 항체 요법을 위한 치료 패러다임
|
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
|
KR20240150768A
(ko)
|
2022-02-17 |
2024-10-16 |
에이티비 테라퓨틱스 |
리보솜 불활성화 단백질을 포함하는 재조합 면역독소
|
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
|
CN119365780A
(zh)
|
2022-04-06 |
2025-01-24 |
拉利玛生物医药公司 |
用于监测共济蛋白替代疗法的共济蛋白敏感性标志物
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|
|
CN119768427A
(zh)
|
2022-05-18 |
2025-04-04 |
詹森生物科技公司 |
用于评估il23抗体以及用il23抗体治疗银屑病关节炎的方法
|
|
WO2023240201A1
(en)
|
2022-06-08 |
2023-12-14 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
|
|
WO2024023246A1
(en)
|
2022-07-28 |
2024-02-01 |
Philogen S.P.A. |
Antibody binding to pd1
|
|
KR20250049549A
(ko)
|
2022-08-08 |
2025-04-11 |
에이티비 테라퓨틱스 |
CD79b에 대한 인간화된 항체
|
|
WO2024038095A1
(en)
|
2022-08-16 |
2024-02-22 |
Iome Bio |
NOVEL ANTI-RGMb ANTIBODIES
|
|
EP4587474A2
(en)
|
2022-09-14 |
2025-07-23 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
US20240101718A1
(en)
|
2022-09-28 |
2024-03-28 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
|
CN119998326A
(zh)
|
2022-10-03 |
2025-05-13 |
图尔库大学 |
具有新型二硫键的超稳定抗体片段
|
|
TW202417057A
(zh)
|
2022-10-26 |
2024-05-01 |
大陸商同潤生物醫藥(上海)有限公司 |
人源化的l1cam抗體藥物偶聯物
|
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
|
WO2024105205A1
(en)
|
2022-11-17 |
2024-05-23 |
Bayer Aktiengesellschaft |
Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
|
|
EP4619044A1
(en)
|
2022-11-17 |
2025-09-24 |
Hans-Georg Lerchen |
Antibody-drug-conjugates cleavable in a tumor microenvironment
|
|
EP4623001A1
(en)
|
2022-11-22 |
2025-10-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
|
EP4659023A1
(en)
|
2023-02-03 |
2025-12-10 |
Immusmol SAS |
Method of predicting success of a cancer therapy
|
|
CN120659814A
(zh)
|
2023-02-13 |
2025-09-16 |
浙江大学绍兴研究院 |
双特异性抗体及其应用
|
|
KR20250157375A
(ko)
|
2023-03-08 |
2025-11-04 |
암젠 인크 |
이중특이적 분자에 대한 제어된 빙핵 형성 동결건조 공정
|
|
TW202442682A
(zh)
|
2023-04-14 |
2024-11-01 |
美商英塞特公司 |
抗ＴＧＦβＲ２／ＰＤ－１雙特異性抗體之用途
|
|
AU2024274397A1
(en)
|
2023-05-17 |
2025-11-13 |
Syndax Pharmaceuticals, Inc. |
Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
|
|
WO2024251787A1
(en)
|
2023-06-05 |
2024-12-12 |
Pure Biologics Spólka Akcyjna |
Anti ror1 antibodies and method of use
|
|
WO2024251839A1
(en)
|
2023-06-05 |
2024-12-12 |
Pure Biologics Spólka Akcyjna |
Anti-garp antibodies and methods of use
|
|
AU2024302269A1
(en)
|
2023-06-14 |
2025-11-13 |
Amgen Inc. |
T cell engager masking molecules
|
|
WO2025007195A1
(en)
|
2023-07-05 |
2025-01-09 |
CSL Innovation Pty Ltd |
Methods of treating or preventing a complication of sickle cell disease
|
|
WO2025024272A1
(en)
|
2023-07-23 |
2025-01-30 |
Incyte Corporation |
Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody
|
|
US20250051463A1
(en)
|
2023-07-31 |
2025-02-13 |
Astrazeneca Ab |
Cd123 antibody-drug conjugates and methods of using the same
|
|
WO2025040598A2
(en)
|
2023-08-18 |
2025-02-27 |
Immatics Biotechnologies Gmbh |
Peptides displayed by mhc for use in immunotherapy against different types of cancer
|
|
TW202517674A
(zh)
|
2023-10-19 |
2025-05-01 |
德商拜耳廠股份有限公司 |
抗gpc3抗體及其放射性結合物
|
|
WO2025122695A1
(en)
|
2023-12-06 |
2025-06-12 |
Incyte Corporation |
Combination therapy comprising dgk inhibitors and pd-1/pd-l1 inhibitors
|
|
WO2025155991A2
(en)
|
2024-01-19 |
2025-07-24 |
Bpgbio, Inc. |
Predictive biomarkers for response to coenzyme q10 treatment in pancreatic cancer
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|
|
WO2025180665A1
(en)
|
2024-02-28 |
2025-09-04 |
Evotec International Gmbh |
Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
|
|
WO2025196691A1
(en)
|
2024-03-20 |
2025-09-25 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
WO2025202545A1
(en)
|
2024-03-27 |
2025-10-02 |
Turun Yliopisto |
Immunocomplex antibodies and non-competitive immunoassay for the detection of testosterone
|
|
WO2025226603A1
(en)
|
2024-04-22 |
2025-10-30 |
Surface Oncology, LLC |
Methods for treating cancer using anti-ccr8 antibodies
|
|
US20250325664A1
(en)
|
2024-04-22 |
2025-10-23 |
Incyte Corporation |
Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor
|
|
WO2025242726A1
(en)
|
2024-05-21 |
2025-11-27 |
Onconick Ltd. |
Antibody binding to FGFR1 and conjugates comprising the same
|
|
WO2025257588A1
(en)
|
2024-06-10 |
2025-12-18 |
Affimed Gmbh |
Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
|
|
WO2025256977A1
(en)
|
2024-06-13 |
2025-12-18 |
Bayer Aktiengesellschaft |
Novel igm and igg cleaving enzymes
|
|
WO2025256978A1
(en)
|
2024-06-13 |
2025-12-18 |
Bayer Aktiengesellschaft |
Variants of igm and igg cleaving enzymes
|